<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007080</url>
  </required_header>
  <id_info>
    <org_study_id>CR108966</org_study_id>
    <secondary_id>2020-005720-11</secondary_id>
    <secondary_id>VAC31518COV3006</secondary_id>
    <nct_id>NCT05007080</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive</brief_title>
  <acronym>HORIZON 2</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Adaptive Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in Healthy Adolescents From 12 to 17 Years Inclusive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety, reactogenicity, and humoral immune&#xD;
      response of Ad26.COV2.S or placebo administered intramuscularly (IM) as a 1-dose schedule or&#xD;
      as a 2-dose schedule (56-day interval) in adolescents (Part 1 and Part 2); and to demonstrate&#xD;
      non-inferiority (NI) of immune responses induced by 1 dose or 2 doses or of a lower, to be&#xD;
      determined, dose level of Ad26.COV2.S in adolescents versus 1 or 2 doses of Ad26.COV2.S in&#xD;
      young adults (Part 2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Available safety, immunogenicity and efficacy data from the Ad26.COV2.S vaccine development&#xD;
      program supports initiating evaluation of Ad26.COV2.S in the pediatric population.&#xD;
      Ad26.COV2.S will be evaluated in the pediatric population through a dose-confirmation&#xD;
      approach. Ad26.COV2.S (also known as Ad26COVS1, VAC31518, JNJ-78436735) is a monovalent&#xD;
      vaccine composed of a recombinant, replication-incompetent human adenovirus type 26 (Ad26)&#xD;
      vector, constructed to encode the severe acute respiratory syndrome coronavirus(-2)&#xD;
      (SARS-CoV-2) spike (S) protein, stabilized in its prefusion conformation. This study is a&#xD;
      2-part study: Part 1 consists of a Dose Selection Cohort and Part 2 consists of an Expansion&#xD;
      Cohort with dose levels and dose regimen selected after a review of the data from Part 1.&#xD;
      Both Parts 1 and 2 are of 13 months each with each part consisting of a screening phase (up&#xD;
      to 28 days), study period (up to 12 months) including vaccination phase (up to 56 days) and a&#xD;
      safety and immunogenicity follow-up phase (up to 12 months after first vaccination).&#xD;
      Assessments like immunogenicity (such as humoral and cellular immune responses), safety and&#xD;
      reactogenicity (such as adverse events [AEs] monitoring) will be performed in this study.&#xD;
      Other safety assessments include vital signs measurements (heart rate, supine systolic and&#xD;
      diastolic blood pressure, respiratory rate, and body temperature) and physical examinations.&#xD;
      The overall study duration from enrolment of the first participant until study completion is&#xD;
      expected to be up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 28, 2021</start_date>
  <completion_date type="Anticipated">September 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Solicited Local Adverse Events (AEs) 7 Days Post-dose 1</measure>
    <time_frame>7 days post-dose 1 (Day 8)</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs are pre-defined local (at the injection site) AEs for which participants are specifically asked and which are noted by participants in their reactogenicity diary for 7 days post each vaccination. Solicited local AEs are: injection site pain/tenderness, erythema, swelling at the vaccination site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Solicited Local Adverse Events (AEs) 7 Days Post-dose 2</measure>
    <time_frame>7 days post-dose 2 (Day 64)</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs are pre-defined local (at the injection site) AEs for which participants are specifically asked and which are noted by participants in their reactogenicity diary for 7 days post each vaccination. Solicited local AEs are: injection site pain/tenderness, erythema, swelling at the vaccination site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Solicited Systemic AEs 7 Days Post-dose 1</measure>
    <time_frame>7 days post-dose 1 (Day 8)</time_frame>
    <description>Participants will be instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (day of vaccination and the subsequent 7 days) for the following solicited systemic AEs: fatigue, headache, nausea, and myalgia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Solicited Systemic AEs 7 Days Post-dose 2</measure>
    <time_frame>7 days post-dose 2 (Day 64)</time_frame>
    <description>Participants will be instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for following solicited systemic AEs: fatigue, headache, nausea, and myalgia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Unsolicited AEs 28 Days Post-dose 1</measure>
    <time_frame>28 days post-dose 1 (Day 29)</time_frame>
    <description>Unsolicited AEs are all AEs for which the participant is not specifically questioned in the participant's reactogenicity diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Unsolicited AEs 28 Days Post-dose 2</measure>
    <time_frame>28 days post-dose 2 (Day 85)</time_frame>
    <description>Unsolicited AEs are all AEs for which the participant is not specifically questioned in the participant's reactogenicity diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Medically-attended Adverse Events (MAAEs)</measure>
    <time_frame>From the first vaccination until 6 months post-dose 1 (Up to Day 184)</time_frame>
    <description>MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits will not be considered medically-attended visits. New onset of chronic diseases will be collected as part of the MAAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with MAAEs</measure>
    <time_frame>From the first vaccination until 6 months post-dose 2 (Up to Day 240)</time_frame>
    <description>MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits will not be considered medically-attended visits. New onset of chronic diseases will be collected as part of the MAAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with MAAEs Leading to Discontinuation</measure>
    <time_frame>Until completion of the participant's last study related procedure (Up to Day 380)</time_frame>
    <description>MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits will not be considered medically-attended visits. New onset of chronic diseases will be collected as part of the MAAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 380</time_frame>
    <description>SAE is any untoward medical occurrence that at any dose results in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Adverse Events of Special Interest (AESI) (Including Multisystem Inflammatory Syndrome in Children [MIS-C])</measure>
    <time_frame>Up to Day 380</time_frame>
    <description>Number of participants with AESI (including MIS-C) will be reported. Thrombosis with thrombocytopenia syndrome (TTS) and MIS-C are considered to be AESIs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Serological Response to Vaccination Measured by Enzyme-linked Immunosorbent Assay (S-ELISA) or Equivalent Assay 28 Days Post-dose 1</measure>
    <time_frame>28 days post-dose 1 (Day 29)</time_frame>
    <description>Serological response to vaccination will be measured by S-ELISA (ELISA Units/mL [EU/mL]) or equivalent assay 28 days post-dose 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Serological Response to Vaccination Measured by S-ELISA or Equivalent Assay 14 Days Post-dose 2</measure>
    <time_frame>14 days post-dose 2 (Day 71)</time_frame>
    <description>Serological response to vaccination will be measured by S-ELISA (ELISA Units/mL [EU/mL]) or equivalent assay 14 days post-dose 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Serological Response to Vaccination Measured by Virus Neutralization Assay (VNA) Titers 28 Days Post-dose 1</measure>
    <time_frame>28 days post-dose 1 (Day 29)</time_frame>
    <description>Serological response to vaccination will be measured by VNA titers 28 days post-dose 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Serological Response to Vaccination Measured by VNA Titers 14 Days Post-dose 2</measure>
    <time_frame>14 days post-dose 2 (Day 71)</time_frame>
    <description>Serological response to vaccination will be measured by VNA titers 14 days post-dose 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in Seroresponse Rate of VNA to 28 Days Post-dose 1</measure>
    <time_frame>Baseline to Day 29 (28 days post-dose 1)</time_frame>
    <description>Change from baseline in seroresponse rate of VNA to 28 days post-dose 1 (Day 29) will be reported. Seroresponse rate is defined as the proportion of participants with a baseline sample value of less than or equal to the lower limit of quantitation (LLOQ; [&lt;= LLOQ]) and the postbaseline sample is strictly greater than the LLOQ (&gt; LLOQ). If the baseline sample value is strictly greater than the LLOQ (&gt;LLOQ), the seroresponse rate is defined as the proportion of individuals with a postbaseline sample value representing an at least 4-fold (greater than or equal to [&gt;=] 4-fold) increase from the baseline sample value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in Seroresponse Rate of VNA to 14 Days Post-dose 2</measure>
    <time_frame>Baseline to Day 71 (14 days post-dose 2)</time_frame>
    <description>Change from baseline in seroresponse rate of VNA to 14 days post-dose 2 (Day 71) will be reported. Seroresponse rate is defined as the proportion of participants with a baseline sample value of less than or equal to the lower limit of quantitation (LLOQ; [&lt;= LLOQ]) and the postbaseline sample is strictly greater than the LLOQ (&gt; LLOQ). If the baseline sample value is strictly greater than the LLOQ (&gt;LLOQ), the seroresponse rate is defined as the proportion of individuals with a postbaseline sample value representing an at least 4-fold (&gt;= 4-fold) increase from the baseline sample value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Humoral Immune Response Expressed by the Geometric Mean Titer (GMT) of VNA 28 Days Post-dose 1 in Adolescents and Young Adults</measure>
    <time_frame>28 days post-dose 1 (Day 29)</time_frame>
    <description>Non-inferiority (NI) will be assessed in terms of humoral immune response expressed by the GMT of VNA 28 days post-dose 1 in adolescents and young adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Humoral Immune Response Expressed by the Seroresponse Rate of the VNA 28 Days after First Vaccination in Adolescents and Young adults</measure>
    <time_frame>28 days after first vaccination (Day 29)</time_frame>
    <description>NI will be assessed in terms of humoral immune response expressed by the seroresponse rate of the VNA 28 days after first vaccination in adolescents and young adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Humoral Immune Response Expressed by the GMT of VNA 28 Days Post-dose 1 in Adolescents</measure>
    <time_frame>28 days post-dose 1 (Day 29)</time_frame>
    <description>NI will be assessed in terms of humoral immune response expressed by the GMT of VNA, 28 days post-dose 1 in adolescents.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Humoral Immune Response Expressed by the GMT of VNA 14 Days Post-dose 2 in Young Adults</measure>
    <time_frame>14 days post-dose 2 (Day 71)</time_frame>
    <description>NI will be assessed in terms of humoral immune response expressed by the GMT of VNA, 14 days post-dose 2 in young adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Humoral Immune Response Expressed by the Seroresponse Rate of the VNA 28 Days after First Vaccination in Adolescents</measure>
    <time_frame>28 days after first vaccination (Day 29)</time_frame>
    <description>NI will be assessed in terms of humoral immune response expressed by the seroresponse rate of the VNA 28 days after first vaccination in adolescents.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Humoral Immune Response Expressed by the Seroresponse Rate of the VNA 14 Days Post-dose 2 in Young Adults</measure>
    <time_frame>14 days post-dose 2 (Day 71)</time_frame>
    <description>NI will be assessed in terms of humoral immune response expressed by the seroresponse rate of the VNA 14 days post-dose 2 in young adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Serological Response to Vaccination as Measured by the GMT of VNA 14 Days Post-dose 2 in Adolescents</measure>
    <time_frame>14 days post-dose 2 (Day 71)</time_frame>
    <description>Serological response to vaccination will be measured by the GMT of VNA, 14 days post-dose 2 in adolescents.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Serological Response to Vaccination as Measured by the GMT of VNA 28 Days Post-dose 1 in Young Adults</measure>
    <time_frame>28 days post-dose 1 (Day 29)</time_frame>
    <description>Serological response to vaccination will be measured by the GMT of VNA, 28 days post-dose 1 in young adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Humoral Immune Response Expressed by the Seroresponse Rate of the VNA 14 Days Post-dose 2 in Adolescents</measure>
    <time_frame>14 days post-dose 2 (Day 71)</time_frame>
    <description>NI will be assessed in terms of humoral immune response expressed by the seroresponse rate of the VNA 14 days post-dose 2 in adolescents.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Humoral Immune Response Expressed by the Seroresponse Rate of the VNA 28 Days Post-dose 1 in Young Adults</measure>
    <time_frame>28 days post-dose 1 (Day 29)</time_frame>
    <description>NI will be assessed in terms of humoral immune response expressed by the seroresponse rate of the VNA 28 days post-dose 1 in young adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Humoral Immune Response Expressed by the GMT of VNA 14 Days Post-dose 2 in Adolescents and Young Adults</measure>
    <time_frame>14 days post-dose 2 (Day 71)</time_frame>
    <description>NI will be assessed in terms of humoral immune response expressed by the GMT of VNA 14 days post-dose 2 in adolescents and young adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Humoral Immune Response Expressed by the Seroresponse Rate of the VNA 14 Days Post-dose 2 in Adolescents and Young Adults</measure>
    <time_frame>14 days post-dose 2 (Day 71)</time_frame>
    <description>NI will be assessed in terms of humoral immune response expressed by the seroresponse rate of the VNA 14 days post-dose 2 in adolescents and young adults.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Severe Acute Respiratory Syndrome Coronavirus(-2) (SARS-CoV-2) or Individual SARS-CoV-2 Protein Binding Antibody Titers as Measured by S-ELISA (or Equivalent Assay)</measure>
    <time_frame>Days 1, 29, 57, 71, 184, 366 (Parts 1 and 2)</time_frame>
    <description>SARS-CoV-2 or individual SARS-CoV-2 proteins (example, S protein) binding antibody titers as measured by S-ELISA (or equivalent assay) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: SARS-CoV-2 Neutralizing Antibody Titers as Measured by VNA Titers</measure>
    <time_frame>Days 1, 29, 57, 71, 184, 366 (Parts 1 and 2)</time_frame>
    <description>SARS-CoV-2 neutralizing antibody titers as measured by VNA titers will be reported.</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">4350</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 1 [Standard Volume])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1-dose of Ad26.COV2.S at dose level 1 (standard volume) on Day 1 followed by placebo on Day 57. At unblinded phase (6 months after the first vaccination), participants who received placebo will receive 1- or 2-dose active vaccine regimen in an open-label manner and participants who received active vaccine may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 1 [Lower Volume])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1-dose of Ad26.COV2.S at dose level 1 (lower volume) on Day 1 followed by placebo on Day 57. At unblinded phase (6 months after the first vaccination), participants who received placebo will receive 1- or 2-dose active vaccine regimen in an open-label manner and participants who received active vaccine may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 2): 1-Dose Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1-dose of Ad26.COV2.S at dose level 2 on Day 1 followed by placebo on Day 57. At unblinded phase (6 months after the first vaccination), participants who received placebo will receive 1- or 2-dose active vaccine regimen in an open-label manner and participants who received active vaccine may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 3): 1-Dose Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1-dose of Ad26.COV2.S at dose level 3 on Day 1 followed by placebo on Day 57. At unblinded phase (6 months after the first vaccination), participants who received placebo will receive 1- or 2-dose active vaccine regimen in an open-label manner and participants who received active vaccine may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 2): 2-Doses Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 doses of Ad26.COV2.S at dose level 2 on Day 1 and Day 57. Participants who received active vaccine may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 3): 2-Doses Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 doses of Ad26.COV2.S at dose level 3 on Day 1 and Day 57. Participants who received active vaccine may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (Dose Selection Cohort): Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 2 doses of placebo on Day 1 and Day 57. At unblinded phase (6 months after the first vaccination), participants who received placebo will receive 1- or 2-dose active vaccine regimen in an open-label manner at a selected dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 1 [Standard or Lower Volume])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1-dose of Ad26.COV2.S at dose level 1 (standard or lower volume) on Day 1. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 2): 1-Dose Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1-dose of Ad26.COV2.S at dose level 2 on Day 1. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 3): 1-Dose Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1-dose of Ad26.COV2.S at dose level 3 on Day 1. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Placebo: 1-Dose Regimen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 1-dose of placebo on Day 1. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 2): 2-Doses Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 doses of Ad26.COV2.S at dose level 2 on Day 1 and Day 57. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 3): 2-Doses Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 doses of Ad26.COV2.S at dose level 3 on Day 1 and Day 57. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Selected dose level [SDL])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 doses of SDL on Day 1 and Day 57. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Placebo: 2-Doses Regimen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 2 doses of placebo on Day 1 and Day 57. After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.COV2.S</intervention_name>
    <description>Ad26.COV2.S will be administered as intramuscular (IM) injection.</description>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 1 [Lower Volume])</arm_group_label>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 1 [Standard Volume])</arm_group_label>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 2): 1-Dose Regimen</arm_group_label>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 2): 2-Doses Regimen</arm_group_label>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 3): 1-Dose Regimen</arm_group_label>
    <arm_group_label>Part 1 (Dose Selection Cohort): Ad26.COV2.S (Dose Level 3): 2-Doses Regimen</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 1 [Standard or Lower Volume])</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 2): 1-Dose Regimen</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 2): 2-Doses Regimen</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 3): 1-Dose Regimen</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 3): 2-Doses Regimen</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Selected dose level [SDL])</arm_group_label>
    <other_name>Ad26COVS1, VAC31518, JNJ-78436735</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as IM injection.</description>
    <arm_group_label>Part 1 (Dose Selection Cohort): Placebo</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Placebo: 1-Dose Regimen</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion Cohort): Placebo: 2-Doses Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant's age is 12 to 17 years of age at the time of first vaccination&#xD;
&#xD;
          -  Participant must be healthy, in the investigator's clinical judgement, as confirmed by&#xD;
             medical history, physical examination, and vital signs performed at screening, and&#xD;
             must not have comorbidities related to an increased risk of severe coronavirus&#xD;
             disease-2019 (COVID-19)&#xD;
&#xD;
          -  Participant agrees to not donate bone marrow, blood, and blood products from the first&#xD;
             study vaccine administration until 3 months after receiving the last dose of study&#xD;
             vaccine&#xD;
&#xD;
          -  Participant and/or parent(s)/legal guardian(s) are available and willing to&#xD;
             participate for the duration of the study visits and follow-up&#xD;
&#xD;
          -  Each participant or participant's parent(s)/legal guardian(s) must have access to a&#xD;
             consistent means of contact either by telephone contact or email/computer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has a history of malignancy, bone marrow transplant, or solid organ&#xD;
             transplant within 5 years before screening&#xD;
&#xD;
          -  Participant has a known or suspected allergy, history of anaphylaxis, or other serious&#xD;
             adverse reactions, related to vaccines or their excipients (including specifically the&#xD;
             excipients of the study vaccine)&#xD;
&#xD;
          -  Use of systemic corticosteroids at an immunosuppressive dose (treatment duration more&#xD;
             than 14 days for one course or recurrent use) within 6 months before administration of&#xD;
             study vaccine and during the study&#xD;
&#xD;
          -  Participants with a history of illness or with an ongoing illness that, in the opinion&#xD;
             of the investigator, may pose additional risk to the participant if he/she&#xD;
             participates in the study&#xD;
&#xD;
          -  Any serious, chronic, or progressive disease (example, diabetes, cardiac disease,&#xD;
             hepatic disease, progressive neurological disease or seizure disorder; autoimmune&#xD;
             disease, acquired immunodeficiency syndrome [AIDS] infection, blood dyscrasias,&#xD;
             bleeding diathesis, signs of cardiac or renal failure, or severe malnutrition)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CIPREC</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1119ACN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. General de Agudos Buenos Aires Argentina NICHD CRS</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEMEDIC</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1440CFD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pedro de Elizalde</name>
      <address>
        <city>City of Buenos Aires</city>
        <zip>C1270AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Division-Stamboulian Servicios de Salud</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1425AWK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Barrio Parque. Swiss Medical Group</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Huesped</name>
      <address>
        <city>Ciudad Autonoma De Buenos Aire</city>
        <zip>C1202ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Ninos de Cordoba</name>
      <address>
        <city>Córdoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Platense</name>
      <address>
        <city>La Plata</city>
        <zip>B1900Avg</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Medicas Mar Del Plata</name>
      <address>
        <city>Mar del Plata</city>
        <zip>B7600FYK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIM Clinica Privada</name>
      <address>
        <city>Ramos Mejia</city>
        <zip>B1704ETD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Niño Jesús</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas da Universidade Federal De Minas Geraisnas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericordia de Belo Horizonte</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L2IP - Instituto de Pesquisas Clínicas</name>
      <address>
        <city>Brasília</city>
        <zip>70200-730</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas</name>
      <address>
        <city>Campinas</city>
        <zip>13060-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Núcleo de Medicina Tropical - Universidade Federal do Ceará</name>
      <address>
        <city>Ceará</city>
        <zip>60430-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São José</name>
      <address>
        <city>Criciúma</city>
        <zip>88801-250</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pequeno Principe</name>
      <address>
        <city>Curitiba</city>
        <zip>80.250-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Sao Francisco</name>
      <address>
        <city>Curitiba</city>
        <zip>80810-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação De Medicina Tropical Doutor Heitor Vieira Dourado</name>
      <address>
        <city>Manaus</city>
        <zip>69040-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos e Pesquisas em Moléstias Infecciosas</name>
      <address>
        <city>Natal</city>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas FMRP-USP</name>
      <address>
        <city>Ribeirão Preto</city>
        <zip>14051-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Infectologia Evandro Chagas (INI) - FIOCRUZ</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Nova Iguacu - HGNI DST/AIDS</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>26030-380</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMPC - Consultoria Médica e Pesquisa Clínica</name>
      <address>
        <city>Sorocaba</city>
        <zip>18040-425</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa</name>
      <address>
        <city>Barranquilla</city>
        <zip>080001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medplus Medicina Prepagada S.A.</name>
      <address>
        <city>Bogota</city>
        <zip>110111</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Atencion e Investigacion Medica S.A. - CAIMED</name>
      <address>
        <city>Chia</city>
        <zip>250001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporación Clínica Universidad Cooperativa De Colombia Clínica Ucc</name>
      <address>
        <city>Villavicencio</city>
        <zip>500001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri ramchandra Medical College &amp; Research Institute</name>
      <address>
        <city>Chennai</city>
        <zip>600116</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSS Hospital</name>
      <address>
        <city>Mysore</city>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Supe Heart And Diabetes Hospital and Research Center</name>
      <address>
        <city>Nashik</city>
        <zip>0422002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D.Y.Patil Medical College</name>
      <address>
        <city>Pune</city>
        <zip>411018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAPS Pramukhswami Hospital</name>
      <address>
        <city>Surat</city>
        <zip>395009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centenario Hospital Miguel Hidalgo</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20259</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatría</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAIMED Investigacion en salud S.A de C.V.</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Federico Gomez</name>
      <address>
        <city>Ciudad De Mexico</city>
        <zip>6720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Dr. Manuel Gea González</name>
      <address>
        <city>Ciudad de México</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Salud Publica</name>
      <address>
        <city>Cuernavaca</city>
        <zip>62100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Medicina Familiar 52 IMSS</name>
      <address>
        <city>Estado de México</city>
        <zip>54720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Köhler &amp; Milstein Research SA de CV</name>
      <address>
        <city>Merida</city>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 'Dr. Jose Eleuterio Gonzalez'</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Clinical Research Unit FAM-CRU</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ndlovu Elandsdoorn Site</name>
      <address>
        <city>Dennilton</city>
        <zip>0485</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit</name>
      <address>
        <city>Guateng Province</city>
        <zip>1111</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandukani Research Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHOENIX PHARMA (Pty) Ltd</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre</name>
      <address>
        <city>Soshanguve</city>
        <zip>152</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Witwatersrand - Helen Joseph Hospital - Themba Lethu Hiv Research Centre</name>
      <address>
        <city>Westdene Johannesburg Gauteng</city>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute for Health Sciences</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, Thammasat University</name>
      <address>
        <city>Pathumthani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine Chulalongkorn University</name>
      <address>
        <city>Pathumwan</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>India</country>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

